English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Cancer presents a problem of complexity. Although our understanding of tumor biology has increased expo nen­ tially over recent decades, and we have many available technologies to characterize tumors, whether and when an individual cancer will metastasize remains unknown. Moreover, if metastases do occur, their molecular features may not match those of the primary tumor or other metastases. Ideally, to guide treatment decisions, all micro­ and macrometastases would be identifi ed, biopsied and molecularly analyzed, but this is not currently possible, practical or safe. Th us, investigations are now focusing on blood­based assays that detect and characterize circulating tumor cells or circulating tumor DNA (a component of cell­free DNA). Th ese minimally invasive, real­time ‘liquid biopsies’ can be performed at multiple intervals to monitor disease and tailor cancer therapy. It is as yet unknown whether these represent com­ peting technologies or if they should be used together. Tumors are heterogeneous and tend to change over

Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?